Related Experiment Video
Updated: Dec 26, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Characterization of PD-L1 binding sites by a combined FMO/GRID-DRY approach
Roberto Paciotti1, Mariangela Agamennone2, Cecilia Coletti2
1Department of Pharmacy, Università "G. D'Annunzio" Di Chieti-Pescara, Chieti, Italy. r.paciotti@unich.it.
Abstract:
The programmed cell death protein 1 (PD-1) and its ligand, PD-L1, constitute an important co-inhibitory immune checkpoint leading to downregulation of immune system. Tumor cells developed a strategy to trigger PD-1/PD-L1 pathway reducing the T cell anticancer activity. Anti-PD-L1 small drugs, generally with improved pharmacokinetic and technological profiles than monoclonal antibodies, became an attractive research topic. Nevertheless, still few works have been published on the chemical features of possible binding sites. In this work, we applied a novel computational protocol based on the combination of the ab initio Fragment Molecular Orbital (FMO) method and a newly developed GRID-DRY approach in order to characterize the PD-L1 binding sites, starting from PD-1/PD-L1 and PD-L1/BMS-ligands (Bristol-Mayers Squibb ligands) complexes. The FMO method allows the calculation of the pair-residues as well as the ligand-residues interactions with ab initio accuracy, whereas the GRID-DRY approach is an effective tool to investigate hydrophobic interactions, not easily detectable by ab initio methods. The present GRID-DRY protocol is able to determine the energy contributions of each ligand atoms to each hydrophobic interaction, both qualitatively and quantitatively. We were also able to identify the three specific hot regions involved in PD-1/PD-L1 protein-protein interaction and in PD-L1/BMS-ligand interactions, in agreement with preceding theoretical/experimental results, and to suggest a specific pharmacophore for PD-L1 inhibitors.
Insights
Researchers computationally characterized programmed cell death protein 1 ligand (PD-L1) binding sites using novel methods. This study identified key interaction regions and a potential pharmacophore for developing new PD-L1 inhibitors.
Area of Science:
- Computational chemistry
- Immunology
- Drug discovery
Background:
- Programmed cell death protein 1 (PD-1) and its ligand (PD-L1) are crucial immune checkpoints.
- Tumor cells exploit the PD-1/PD-L1 pathway to evade immune responses.
- Anti-PD-L1 small drugs are promising cancer therapeutics, but their binding site characteristics are underexplored.
Purpose of the Study:
- To computationally characterize the binding sites of PD-L1.
- To identify key interaction regions in PD-L1 for protein-protein and ligand-protein interactions.
- To propose a pharmacophore for the development of novel PD-L1 inhibitors.
Main Methods:
- Utilized a novel computational protocol combining ab initio Fragment Molecular Orbital (FMO) and GRID-DRY approaches.
- Analyzed PD-1/PD-L1 and PD-L1/BMS-ligand complexes.
- Calculated pair-residue and ligand-residue interactions with ab initio accuracy and investigated hydrophobic interactions.
Main Results:
- Identified three specific hot regions involved in PD-1/PD-L1 and PD-L1/BMS-ligand interactions.
- The GRID-DRY protocol quantitatively assessed energy contributions of ligand atoms to hydrophobic interactions.
- Results align with previous theoretical and experimental findings.
Conclusions:
- The study provides detailed insights into PD-L1 binding site characteristics.
- The identified pharmacophore can guide the design of more effective anti-PD-L1 small drugs.
- This computational approach enhances understanding for targeted cancer immunotherapy development.
More Related Videos
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
06:05Author Spotlight: Multiplex Immunofluorescence Combined with Spatial Image Analysis for the Clinical and Biological Assessment of the Tumor Microenvironment
Published on: June 2, 2023